ARUP Laboratories
500 Chipeta Way – Salt Lake City, UT 84108
(800)522-2787 - www.aruplab.com
Julio C. Delgado, M.D. M.S., Director of Laboratories

*****Example Report*****

Patient Age/Gender: Unknown Unknown
Printed: 18-Dec-19 09:21:01

Procedure	Result	Units	Ref Interval	Accession	Collected	Received	Reported/ Verified
Number of Markers	13	markers		19-344-900212	10-Dec-19 12:00:00	10-Dec-19 14:35:00	11-Dec-19 08:42:08
B-ALL MRD (COG Protocol) Interpretation	See Note f			19-344-900212	10-Dec-19 12:00:00	10-Dec-19 14:35:00	11-Dec-19 08:42:08

10-Dec-19 12:00:00 B-ALL MRD (COG Protocol) Interpretation:
SAMPLE: BONE MARROW

IMPRESSION:
Abnormal immature B-cell population identified. See comment.

Comment:
The abnormal immature B-cells represent 0.63% of total nucleated cells, (the COG result is 1.74% of nucleated mononuclear cells), consistent with residual B-lymphoblastic leukemia/lymphoma (COG day 29 protocol used in evaluation). Phenotypically similar B-lineage lymphoblasts were first reported in peripheral blood and bone marrow flow cytometry studies from Nov 2018 (Accession #xx-xxx-xxxxxx and Accession #xx-xxx-xxxxxx) and in several subsequent studies, most recently in a CSF from July 29, 2019 (Accession #xx-xxx-xxxxxx), where they represented 15% of the total leukocytes. A concurrent comprehensive leukemia/lymphoma flow cytometry study (Accession #xx-xxx-xxxxxx), reported phenotypically similar B-lineage lymphoblasts that represent 0.6% of the total leukocytes. (COG day 29 protocol used in evaluation)

Atypical B-lineage lymphoblasts
Positive for: CD9, CD10, CD19, CD34, CD38, dim CD45, CD58, Syto 16
Negative for: CD20, CD71
Aberrant expression: weak CD13/CD33

ANALYSIS:
Nucleated cell differential:
17% Lymphocytes
5% Monocytes
63% Myeloid cells
14% Nucleated erythroid cells
0.1% CD34 positive myeloblasts

Markers run: CD3, CD9, CD10, CD19, CD20, CD13+CD33, CD34, CD38, CD45, CD58, CD71, Syto 16

These results have been reviewed and approved by Tracy George, MD.

10-Dec-19 12:00:00 B-ALL MRD (COG Protocol) Interpretation:
INTERPRETIVE INFORMATION: B-ALL MRD By Flow Cytometry
(COG Protocol)
For Day 29 samples: Limit of detection of B-ALL blasts is 0.01 percent of mononuclear cells.
For Day 8 samples: Limit of detection of B-ALL blasts is 0.01 percent of total nucleated cells.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement A: aruplab.com/CS